Clinical trials: Chronic Glomerulonephritis
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Primary IgA Nephropathy
The MIMIGA Study is a Randomized, Double-blind, Placebo-controlled Crossover Trial Evaluating the Safety and Efficacy of SCFA vs. Placebo. Administered Orally Once Daily With Standard Care, it Aims to Prevent CKD Progression in Biopsy-proven IgA Nephropathy by Modulating the Gut Microbiome.
MIMIGA Study Title: Modification of Intestinal Microbiome in Patients with Primary IgA Nephropathy (IgAN) Objective: To evaluate whether supplementation with short-chain fatty acids (SCFAs)-specifically sodium butyrate-can reduce…
- Trial name
- MIMIGA (NCT07750249)
- Where
- Slovakia
- Volunteers
- 120 people
- Sponsor
- University Hospital, Martin
Focal Segmental Glomerulosclerosis
A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT07268638
- Testing
- Praliciguat (Part A), Praliciguat (Part B)
- Where
- 30 sites in United States
- Volunteers
- 60 people
- Sponsor
- Akebia Therapeutics
Sarcoidosis, Hypercalcemia Due to Sarcoidosis
ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study
ACTHAR Gel has activity in sarcoidosis associated hypercalciuria and calcium dysregulation.
- Trial name
- NCT02155803
- Testing
- ACTHAR Gel (adrenocorticotropic hormone)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Albany Medical College
IgA Nephropathy, Immunoglobulin A Nephropathy
Atrasentan in Patients With IgA Nephropathy
The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.
- Trial name
- ALIGN (NCT04573478)
- Testing
- Atrasentan, Zigakibart
- Where
- 135 sites in United States, Argentina and 18 more
- Volunteers
- 404 people
- Sponsor
- Novartis Pharmaceuticals
Collapsing Glomerulopathy, Glomerulosclerosis, Focal Segmental
Podocyte Retinoids
This is a pilot study of retinoids for patients with unsatisfactory response to conventional treatment of nephrotic syndrome due to focal segmental glomerulosclerosis or minimal change disease, two renal disorders associated with…
- Trial name
- NCT00098020
- Testing
- Isotretinoin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Kidney Failure, Chronic, Diabetic Nephropathies
Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant
This is a 12-month phase 2, prospective, open label study to evaluate the effect of rituximab with mycophenolate mofetil (MMF)on the PRA of 14 highly sensitized patients who just completed an 8 month trial of MMF treatment alone.
- Conditions
- Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
- Trial name
- NCT00446251
- Testing
- Rituximab, Mycophenolate mofetil (MMF)
- Volunteers
- 14 people
- Sponsor
- University of Washington
IgA Nephropathy, Chronic Kidney Disease
Nefecon and Ambrisentan in IgA Nephropathy
Application of Budesonide in Combination with Ambrisentan in the treatment of IgA nephropathy with progression ESKD risk (24-hour urinary protein ≥ 0.5g/24h), observing the degree and safety of reducing urinary protein and…
- Conditions
- IgA Nephropathy, Chronic Kidney Disease, Proteinuria
- Trial name
- BAIN (NCT07030894)
- Testing
- "Nefecon®","Ambrisentan"
- Where
- China
- Volunteers
- 129 people
- Sponsor
- The First Hospital of Jilin University
IGA Nephropathy
Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy
Immunoglobulin A (IgA) nephropathy is the most common type of primary glomerulonephritis in the world. A wealth of literature suggests that vitamin D and its analogs have profound effects on immune system function and glomerular…
- Trial name
- NCT00319761
- Testing
- Calcitriol
- Where
- Hong Kong
- Volunteers
- 10 people
- Sponsor
- Chinese University of Hong Kong
Berger Disease, Bergers Disease
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN
A Phase III, single-arm, multicenter pediatric clinical study evaluating atrasentan in children and adolescents aged 2 to <18 years with primary immunoglobulin A nephropathy (IgAN).
- Conditions
- Berger Disease, Bergers Disease, IgA Nephropathy, Immunoglobulin A Nephropathy
- Trial name
- ADVANCE (NCT07498335)
- Testing
- Drug: Atrasentan
- Where
- 18 sites in United States, China and 5 more
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Kidney Disease, IgA Nephropathy
Pilot Study of Velcade® in IgA Nephropathy
The primary objective of this study is to investigate the ability of Velcade® (bortezomib) to induce complete or partial remission in patients with severe IgA nephropathy.
- Trial name
- NCT01103778
- Testing
- Bortezomib (Velcade®)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- The Rogosin Institute
Focal Segmental Glomerulosclerosis, Nephrotic Syndrome
Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis
The objective of this study is as follows: Perform genetic analysis to define the prevalence of each of the known gene mutations in an unselected cohort of patients with focal segmental glomerulosclerosis (FSGS) Perform a…
- Conditions
- Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Chronic Kidney Disease
- Trial name
- NCT00883636
- Testing
- Cardiovascular Assessment, Renal Assessment, Genetic Evaluation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Northwell Health
Glomerulonephritis, IGA, Renal Insufficiency, Chronic
Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency
IgA nephropathy is the most common primary glomerulonephritis in the world. Because of the poor treatment effect in advanced patients, it is still the main cause of maintenance dialysis.
- Trial name
- NCT04020328
- Testing
- Leflunomide 20 mg+prednisone 0.5mg/kg/d
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Shenzhen Second People's Hospital
Immunoglobulin A Nephropathy, Healthy Subjects
Development of a Metabolic Assessment Tool for Chronic Kidney Disease
The purpose of this study is to examine the variation between individuals in blood lipid metabolites, and the changes in these metabolites in response to omega-3 fatty acids in patients with immunoglobulin A nephropathy (IgAN)…
- Trial name
- NCT01838239
- Testing
- Fish Oil
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Primary IgA Nephropathy; Autoimmune Hepatitis
Relative Bioavailability Study of HR19042 in Healthy Subjects
This is a single-center, randomized, open-label, three-period, dual Latin square crossover study. Primary Objective： 1. To evaluate the oral relative bioavailability of HR19042 Capsules compared with budesonide delayed-release…
- Trial name
- NCT06922305
- Testing
- HR19042 Capsule, Tarpeyo®, Budenofalk®
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Kidney Diseases, Kidney Diseases, Chronic
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN).
- Conditions
- Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis
- Trial name
- NCT06858319
- Testing
- zigakibart
- Where
- 26 sites in United States, Argentina and 7 more
- Volunteers
- 220 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Nephropathies, Lupus Nephritis
Retrospective Analysis of Renal Prognosis in Patients With Chronic Kidney Disease
During 1993 and 2006, a total of 987 patients older than 20 years underwent native kidney biopsy at the Renal Division of this hospital.
- Conditions
- Diabetic Nephropathies, Lupus Nephritis, Rapidly Progressive Glomerulonephritis, Chronic Kidney Diseases
- Trial name
- NCT03201406
- Where
- 2 sites in Taiwan
- Volunteers
- 837 people
- Sponsor
- National Taiwan University Hospital
Proteinuria
Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria
The primary objective of this study is to assess the impact of proteinuria on the pharmacokinetic (PK) of a single dose of ALXN1720 in participants with proteinuria.
- Trial name
- NCT05314231
- Testing
- ALXN1720
- Where
- 2 sites in South Korea
- Volunteers
- 13 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Kidney Insufficiency, Diabetes Mellitus
Plant Versus Animal Dietary Protein and the Effect on Proteinuria
The purpose of this study is to investigate if a diet high in plant protein improves kidney function in patients with kidney insufficiency and diabetes and/or hypertension and/or glomerulonephritis.
- Conditions
- Kidney Insufficiency, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
- Trial name
- NYPRO (NCT04058951)
- Testing
- High Animal Protein Diet (HAPD), High Plant Protein Diet (HPPD)
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Jens Rikardt Andersen
IgA Nephropathy
A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy
The purpose of this study is to determine if BHV-1400 is effective and safe in the treatment of IgA Nephropathy. Participants will be randomized in a 2:1 ratio to receive either BHV-1400 or placebo.
- Trial name
- NCT07642050
- Testing
- BHV-1400
- Volunteers
- 420 people
- Sponsor
- Biohaven Therapeutics Ltd.